Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy

Autor: A, Custodio Rebollo Aguirre, R, Sánchez Sánchez, A D, González Jiménez, M, Culiañez Casas, I, Mendoza Arnau, M, Rashki, T, Rudolphi Solero, S, Martínez Meca
Rok vydání: 2019
Předmět:
Zdroj: Revista espanola de medicina nuclear e imagen molecular. 39(2)
ISSN: 2253-8089
Popis: To present our initial experience in the combined procedure of intraoperative detection of axillary positive node marked withProspective study, January 2017 - March 2019, 16 breast cancer patients T1-3N1. TNM stage: IIA: 3, IIB: 10, IIIA: 3. Histological type ductal invasive: 14. Molecular subtype: luminal A: 3, luminal B: 9, HER2: 3, basal like: 1. The ML was marked 227±36 days before neoadjuvant chemotherapy (n: 10), or 1-6 days before surgery, on previously identified node by ultrasound visibility marker, hydrogel (n: 3) or three dimensional-3D (n: 3). Axillary lymphadenectomy was undertaken in 10 patients.ML and SLN were identified in the surgery in 93.7% (15/16) of the cases, in 33.3% (5/15) ML was not among SLN, and in only one patient (1/5) was there a discrepancy between the result of ML and SLN (macrometastases vs. negative 0/2). Median number of lymph nodes SLN: 2.2±0.9 (range 1-3) and AD: 13.5±5.2 (range 7-23). In all cases, histopathological analysis of ML,Placing of
Databáze: OpenAIRE